|
1
|
Walker S: Updates in non-small cell lung
cancer. Clin J Oncol Nurs. 12:587–596. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu Q, Wang Y, Liu H, Meng S, Zhou S, Xu J,
Schmid-Bindert G and Zhou C: Treatment outcome for patients with
primary NSCLC and synchronous solitary metastasis. Clin Transl
Oncol. 15:802–809. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan F, Shi Y, Wang Y, Ding L, Yuan X and
Sun Y: Icotinib, a selective EGF receptor tyrosine kinase
inhibitor, for the treatment of non-small-cell lung cancer. Future
Oncol. 11:385–397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kosaka T, Yatabe Y, Endoh H, Yoshida K,
Hida T, Tsuboi M, Tada H, Kuwano H and Mitsudomi T: Analysis of
epidermal growth factor receptor gene mutation in patients with
non-small cell lung cancer and acquired resistance to gefitinib.
Clin Cancer Res. 12:5764–5769. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Onitsuka T, Uramoto H, Nose N, Takenoyama
M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to
gefitinib: The contribution of mechanisms other than the T790M, MET
and HGF status. Lung Cancer. 68:198–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sos ML, Rode HB, Heynck S, Peifer M,
Fischer F, Klüter S, Pawar VG, Reuter C, Heuckmann JM, Weiss J, et
al: Chemogenomic profiling provides insights into the limited
activity of irreversible EGFR Inhibitors in tumor cells expressing
the T790M EGFR resistance mutation. Cancer Res. 70:868–874. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ju L and Zhou C: Association of integrin
beta1 and c-MET in mediating EGFR TKI gefitinib resistance in
non-small cell lung cancer. Cancer Cell Int. 13:152013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eng C: PTEN: One gene, many syndromes. Hum
Mutat. 22:183–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ortega-Molina A and Serrano M: PTEN in
cancer, metabolism, and aging. Trends Endocrinol Metab. 24:184–189.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Soria JC, Lee HY, Lee JI, Wang L, Issa JP,
Kemp BL, Liu DD, Kurie JM, Mao L and Khuri FR: Lack of PTEN
expression in non-small cell lung cancer could be related to
promoter methylationc. Clin Cancer Res. 8:1178–1184.
2002.PubMed/NCBI
|
|
12
|
Mezzapelle R, Miglio U, Rena O, Paganotti
A, Allegrini S, Antona J, Molinari F, Frattini M, Monga G, Alabiso
O and Boldorini R: Mutation analysis of the EGFR gene and
downstream signalling pathway in histologic samples of malignant
pleural mesothelioma. Br J Cancer. 108:1743–1749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu H, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jones HE, Goddard L, Gee JM, Hiscox S,
Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE and
Nicholson RI: Insulin-like growth factor-I receptor signalling and
acquired resistance to gefitinib (ZD1839; Iressa) in human breast
and prostate cancer cells. Endocr Relat Cancer. 11:793–814. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boch C, Kollmeier J, Roth A,
Stephan-Falkenau S, Misch D, Grüning W, Bauer TT and Mairinger T:
The frequency of EGFR and KRAS mutations in non-small cell lung
cancer (NSCLC): Routine screening data for central Europe from a
cohort study. BMJ Open. 3:pii. e0025602013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma C, Wei S and Song Y: T790M and acquired
resistance of EGFR TKI: A literature review of clinical reports. J
Thorac Dis. 3:10–18. 2011.PubMed/NCBI
|
|
17
|
Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP,
Wang SH, Liang X and Lu CX: PTEN inhibits the migration and
invasion of HepG2 cells by coordinately decreasing MMP expression
via the PI3K/Akt pathway. Oncol Rep. 23:1593–1600. 2010.PubMed/NCBI
|
|
18
|
Chalhoub N and Baker SJ: PTEN and the
PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leslie NR and Downes CP: PTEN function:
How normal cells control it and tumour cells lose it. Biochem J.
382:1–11. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moon SH, Kim DK, Cha Y, Jeon I, Song J and
Park KS: PI3K/Akt and Stat3 signaling regulated by PTEN control of
the cancer stem cell population, proliferation and senescence in a
glioblastoma cell line. Int J Oncol. 42:921–928. 2013.PubMed/NCBI
|
|
21
|
Fidler MJ, Morrison LE, Basu S, Buckingham
L, Walters K, Batus M, Jacobson KK, Jewell SS, Coon J IV and Bonomi
PD: PTEN and PIK3CA gene copy numbers and poor outcomes in
non-small cell lung cancer patients with gefitinib therapy. Br J
Cancer. 105:1920–1926. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamamoto C, Basaki Y, Kawahara A,
Nakashima K, Kage M, Izumi H, Kohno K, Uramoto H, Yasumoto K,
Kuwano M and Ono M: Loss of PTEN expression by blocking nuclear
translocation of EGR1 in gefitinib-resistant lung cancer cells
harboring epidermal growth factor receptor-activating mutations.
Cancer Res. 70:8715–8725. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamasaki F, Johansen MJ, Zhang D,
Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K,
Mills GB, Hortobagyi GN and Ueno NT: Acquired resistance to
erlotinib in A-431 epidermoid cancer cells requires down-regulation
of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res.
67:5779–5788. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
She QB, Solit DB, Ye Q, O'Reilly KE, Lobo
J and Rosen N: The BAD protein integrates survival signaling by
EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor
cells. Cancer Cell. 8:287–297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mellinghoff IK, Wang MY, Vivanco I,
Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH and
Chute DJ: Molecular determinants of the response of glioblastomas
to EGFR kinase inhibitors. N Engl J Med. 353:2012–2024. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang YS, Wang YH, Xia HP, Zhou SW,
Schmid-Bindert G and Zhou CC: MicroRNA-214 Regulates the Acquired
Resistance to Gefitinib via the PTEN/AKT pathway in EGFR-mutant
cell lines. Asian Pac J Cancer Prev. 13:255–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sos ML, Koker M, Weir BA, Heynck S,
Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P,
et al: PTEN loss contributes to erlotinib resistance in EGFR-mutant
lung cancer by activation of Akt and EGFR. Cancer Res.
69:3256–3261. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ludovini V, Bianconi F, Pistola L, Chiari
R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A,
Flacco A, et al: Phosphoinositide-3-kinase catalytic alpha and KRAS
mutations are important predictors of resistance to therapy with
epidermal growth factor receptor tyrosine kinase inhibitors in
patients with advanced non-small cell lung cancer. J Thorac Oncol.
6:707–715. 2011. View Article : Google Scholar : PubMed/NCBI
|
